December 18, 2024
Genethon newsletter – 2024 Issue Number 2
This last issue of 2024 year highlights several major clinical development and scientific milestones over the past several months for Genethon.
– Positive safety and efficacy results for the gene therapy GNT0004, set it apart from all other Duchenne Muscular Dystrophy treatments.
– Launching of a Phase 2 trial of imlifidase as a… (read more)
May 30, 2024
Genethon newsletter – 2024 Issue Number 1
In this new issue, Frédéric Revah, Genethon’s CEO, reviews the results of gene therapy trial for Duchenne Muscular Dystrophy, sponsored by Genethon at Myology Congress and the advances of the Limb-Girdle Muscular Dystrophy trial with Atamyo, a Genethon’s spin-off.
Also discover recent news of our laboratory, including the creation of… (read more)
